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 Recently developed SCD severity scores are not yet the effective tool needed 
for patient stratification in genotype/phenotype (including response to medical 
interventions) association studies, as well as in the discovery and validation of 
prognosis markers of the largely unpredictable SCD clinical course. In particular, 
the marked reduction of sepsis incidence in younger SCD patients in developed 
countries is just an illustration of the type of problems novel improved pediatric 
severity scores should address.  
 Concerning HbF, our results support previously data. In fact, HbF expression is 
the major determinant of phenotypic severity in SCD. It is the most important 
modulator of the clinical and hematological features of the disease because it is 
unable to enter the HbS polymer and reduces mean corpuscular HbS 
concentration. 
Disease severity association with high leucocyte count may reflect chronic 
inflammation, whereas its association with elevated RDW denotes anisocytosis 
and, possibly, an increased number of irreversible sickle cells. 
Results 
Sickle Cell Disease (SCD), one of the most common autosomal recessive hereditary anemia, is caused by a mutation in the β-globin gene 
(HBB:c.20A>T) on 11p15.5. This originates a hemoglobin variant named HbS, as opposed to the normal adult HbA. HbS ability to 
polymerize when deoxygenated gives rise to abnormal sickled red blood cells  (Fig.1).  
SCD is a paradigm of a monogenic disorder under polygenic and environmental control. This aetiopathogenic architecture leads to marked 
clinical heterogeneity with the emergence of multiple and diverse subphenotypes, which makes the patients severity stratification 
particularly difficult1.  
 
 
Subjects: 99 paediatric SS patients (Table I) followed-up in two general hospitals in Greater 
Lisbon area.  
Candidate gene genotyping:  BCL11A, CD36, EDN1, HBA, HBB cluster (including HBG),  HBS1L-
MYB, ITGA4, HMOX1,  NOS3, THBS1 and VCAM1. 
Statistical analysis: Data were extracted from hospital records and entered into a database. 
The normality of scores distribution was tested with Shapiro-Wilk test (α=0.05) and their 
statistical relationship was evaluated by Spearman correlation. Inter-rater agreement 
regarding the severity groups defined by each score was assessed by weighted kappa 
measure.  
Association studies between severity scores and candidate genotypes, as well as with 
hematological and biochemical biomarkers were performed using T/test ANOVA parametric 
tests or Mann-Whitney/Kuskal-Wallis non-parametric tests, using the false discovery rate 
(FDR) for multiple testing correction.  
All the statistical analysis was performed with SPSS v20. 
 
 
 
 
 
 
 
 
 
 Although statistically significant, this 
weak positive correlation, coupled with 
a fair inter-rater agreement (κ value) of 
0.281, suggests the compared severity 
scores, although overall convergent, 
are measuring different aspects of the 
phenotype, at different developmental 
stages (paediatric versus adult) and 
with different weights (Fig. 2). 
 
 Both DSS and PSS displayed a non-
normal (p<0.01) multimodal 
distribution. The Spearman’s ρ 
correlation coefficient between DSS and 
PSS was 0.280 which is significant at the 
2-tailed 0.01 level.  
Fig.1. Normal red blood cells 
and a sickled  one.  
(In www.abbotlab.wordpress.com) 
Table I. Characterisation of SCD (SS) patient 
population sample 
No. of patients  
(sex; ethnicity) 
99 
(54% males; 61% 
Angolan; 97% of Sub-
Saharan origin) 
Entry age (year) 
median  
interquartile range 
total range 
 
2.3  
0.7-4.7 
0.1 – 16.9 
Current agea (year) 
median  
interquartile range 
total range 
 
9.9  
6.7-12.6 
2.9 – 21.7 
Total follow-up 
(person*year) 
557 
Follow-up/patient  
(median; year)  
5.0 
No. of contributing 
clinical centres 
2  
Paediatric Departments 
 
 The evaluated patients were mostly (97%) of Sub-Saharan African ancestry 
and presented an M/F ratio of 1.17, a median current age of 9.9 years, and a 
median follow-up/patient of 5.0 years (Table I). 
Regarding the association studies, statistically significant relationships are 
observed , after correction for the false discovery rate: 
 DSS and PSS are both negatively associated with high fetal hemoglobin (Hb F) 
levels (Fig. 3.A, 3.B and 3.C).  HbF level was the only biomarker that strongly 
associates with both severity scores. 
 DSS is positively associated with a beta-globin gene cluster polymorphism 
(data not shown), leukocyte count and RDW (Fig 3D and 3.E). 
 
Fig. 2. Comparison of two sickle cell disease severy scores.  
Panels 2.A and 2.B represent the severity distribution of 99 SS subjects according to Disease Severity 
Score or Paediatric Severity Score, respectively. Vertical lines represent the border between lower and 
higher clinical severity. Severity score cut-off values were arbitrary set as DSS = 0.400 and PSS = 40.  
Panel 2.C depicts a scatter plot correlating the two scores in the same group of patients.  
Note that 20 out of the 99 patients scored discordantly by DSS and PSS criteria. 
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Fig. 3. Statistically significant associations between 
severity scores and serum hematological parameters. 
Panels 3.A and 3.B show lower severity scores (concerning  
both DSS and PSS) when high levels of HbF are present 
(upper quartile). 
Panel 3.C reinforces the above result – lower severity 
scores (using DSS categorical data) are preferentially found 
associated with higher HbF levels. 
Panel 3.D and 3.E reveal a positive association between 
DSS and leucocyte count as well as RDW.  
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A number of severity scores have been proposed, aiming at the integration of many clinical dimensions into a meaningful single synthetic measure of morbidity 
and/or risk of death within a given period.  
As part of a wider research on the development and validation of vaso-occlusion early predictors in SCD, we have analysed (i) the correlation between two 
thoroughly developed scores, namely a disease severity score (DSS)2 and a paediatric severity score (PSS)3, and (ii) the association of scores to a number of 
genotypic and phenotypic markers in a series of 99 paediatric SS patients.  
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